by Reshma Anand on  December 15, 2015 at 12:38 PM Corporate News
Natco Pharma and Hetero Receives Indian Drug Regulatory Approval for Hepatitis-C Drug
Two Hyderabad-based drug companies, Natco Pharma and Hetero have received approval for the sale of Hepatitis- C drug from the Drugs Controller General of India (DCGI).

The generic version of the drug, Daclatasvir Dihydrochloride (Daclatasvir) is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection.

Natco Pharma will sell the drug under its brand name 'NATDAC' and has received approval for two dosage levels, 60mg and 30 mg. The price is Rs, 6000 for 60mg and Rs. 4000 for 30 mg, for a bottle of 28 tablets.

"It is the first company in India to get approval for generic Daclatasvir Dihydrochloride (Daclatasvir) tablets, 30 mg & 60 mg, from the Drugs Controller General (India)," Natco said.

"Compared with other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patients subsets," Natco added.

Hetero said its product is generic version of Bristol-Myers Squibb's Daklinza tablets.

"The product in combination with Sofosbuvir is indicated for the treatment of Hepatitis C genotype 3 infections, which is highly prevalent in India," Hetero added.

Source: Medindia

Most Popular on Medindia